Novartis Receives FDA Approval for Rhapsido (remibrutinib) for Chronic Spontaneous Urticaria
Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30, Novartis announced the US FDA approval of its drug, Rhapsido (remibrutinib).